Retatrutide Benefits Beyond the Scale: Knee Pain, Blood Sugar, Sleep Apnea, Liver and Heart, Graded by Evidence

Written by Olha Orlyk. Updated October 27, 2026.

Retatrutide's benefits go well beyond the 28% weight loss that made the headlines. In completed phase 3 trials it cut knee osteoarthritis pain by about three quarters, lowered HbA1c by 2 percentage points in people with type 2 diabetes, reduced sleep apnea severity by 60%, and dropped systolic blood pressure by 14 mmHg. In a phase 2 substudy it cleared liver fat in 93% of people with fatty liver disease. Each of those effects has a number, a trial and a status, and the status matters: some are proven in large phase 3 studies, some rest on a phase 2 substudy, and the one most people care about most, fewer heart attacks and strokes, will not be known until the outcomes trial reads out around 2029.

This article sorts retatrutide's benefits by the strength of the evidence behind them, explains why a drug that hits the glucagon receptor does things to the liver and to energy expenditure that semaglutide and tirzepatide do not, and lists what it has not yet been shown to do.

The pattern is that everything downstream of large weight loss is proven or nearly so, the liver effect is strong but still phase 2, and the hard outcomes that would make retatrutide a heart drug rather than a weight drug are years away. The trial programme and its timeline are tracked in approval watch.

Semaglutide works on one receptor, GLP-1. Tirzepatide adds GIP. Retatrutide adds a third, the glucagon receptor, and that is the source of most of its extra effects. Glucagon is the hormone that tells the liver to release and burn fuel: it raises energy expenditure, increases fat oxidation in the liver and reduces the liver's fat stores directly, independent of how much weight is lost. On its own, glucagon would also raise blood sugar, which is why the GLP-1 and GIP components matter: they drive enough insulin to cancel that out. The net result is a drug that reduces appetite like the others and additionally raises the body's fuel burn, which is why its weight-loss curve keeps falling after the others plateau, and why its liver-fat numbers exceed what weight loss alone would predict. The price is a higher heart rate and more gut effects at the top doses. The receptor pharmacology is explained in what is retatrutide.

Most of retatrutide's benefits are consequences of losing a quarter of your body weight, and that scale of loss is new. In TRIUMPH-1, people starting at an average of 112.7 kg (248 lb) lost 28.3% on 12 mg over 80 weeks, 25.9% on 9 mg and 19.0% on 4 mg, against 2.2% on placebo, and 65% of the 12 mg group ended the trial with a BMI under 30. In the 104-week extension for people with a BMI of 35 or more, the loss reached 30.3%. For comparison, semaglutide 2.4 mg produced about 15% at 68 weeks and tirzepatide 15 mg about 21% at 72 weeks in their own trials. The week-by-week picture is in how fast retatrutide works, and the head-to-head with tirzepatide, including the TRIUMPH-5 direct comparison, in retatrutide vs tirzepatide.

TRIUMPH-4 enrolled 445 adults with obesity and painful knee osteoarthritis and followed them for 68 weeks. On the WOMAC pain scale, which runs from 0 to 10 and started at 6.0, pain fell by 4.5 points on 9 mg and 4.4 on 12 mg, against 2.4 on placebo: a 74 to 76% reduction versus 40%. Seventy-three percent of people on 9 mg had their pain cut by at least 70%, and 12 to 14% reported no knee pain at all, versus 4% on placebo. Physical function improved by a similar margin. The mechanism is mostly mechanical, each kilogram lost removes about four kilograms of load from the knee with every step, plus a drop in inflammatory markers such as CRP. For people who have been told a knee replacement is the next step, this is the benefit with the most immediate practical meaning, and it is the one Lilly is expected to seek a specific indication for.

In TRANSCEND-T2D-1, retatrutide lowered HbA1c by up to 2.0 percentage points from a baseline of 7.9% over 40 weeks, taking up to 90% of participants below the 7% target, while they lost 16.8% of their body weight and were still losing at the end. That HbA1c reduction is in the range of the strongest doses of tirzepatide and larger than semaglutide 1 mg, achieved with a weight loss no diabetes drug has previously produced. People with diabetes lost less than people without it in every GLP-1 trial, and retatrutide is no exception: TRIUMPH-2, in people with obesity and type 2 diabetes, reported 20.8% against 28.3% in TRIUMPH-1. Even so, 20.8% is more than tirzepatide achieved in people without diabetes.

Obstructive sleep apnea improves with any large weight loss, and retatrutide's substudy within TRIUMPH-1 reported the largest improvement yet: the apnea-hypopnea index fell by 36.1 events per hour from a baseline of 58.6, a 60.6% reduction, enough to move many participants from severe to mild disease. Blood pressure fell by 14 mmHg systolic at 12 mg in TRIUMPH-4, a reduction comparable to adding a blood pressure medicine, and non-HDL cholesterol, triglycerides and CRP all fell. What none of this proves is that retatrutide prevents heart attacks and strokes. Semaglutide and tirzepatide have outcomes trials showing that; retatrutide's, TRIUMPH-Outcomes, is running and is not expected to report until around 2029. Until then, the cardiovascular benefit is inferred from risk factors, not demonstrated.

The liver result is the one that most separates retatrutide from the drugs before it, and it is also the one with the least mature evidence. In a substudy of the 48-week phase 2 trial, 98 participants with at least 10% liver fat (metabolic dysfunction-associated steatotic liver disease, MASLD) had their liver fat measured by MRI. At 12 mg it fell by 82% at 24 weeks and 86% at 48 weeks, and 93% of participants reached a normal liver fat level under 5%, against none on placebo. At 8 mg the figures were 82% and 89%. That is far beyond what the weight loss alone predicts, consistent with glucagon-receptor activity in the liver. The caveats are the size, 98 people, and the endpoint: liver fat is a marker, and the trial did not measure inflammation or scarring, which is what the ongoing SYNERGY-Outcomes phase 3 trial in MASH is designed to do.

Retatrutide's benefits are real and most of them are measured in phase 3 trials: record weight loss, three-quarters less knee pain, a two-point drop in HbA1c, a 60% reduction in sleep apnea events, and double-digit falls in blood pressure. Its liver effect is the most striking and the least settled, resting on 98 people in a phase 2 substudy. What it cannot yet claim is the benefit the approved drugs have already proved, fewer heart attacks and strokes, and what it cannot claim at all is availability: it remains an investigational drug until the FDA decides, which is not expected before 2027. We cover the pricing question in how much retatrutide will cost and why the headline number needs context in the big weight-loss headline.

Retatrutide is an investigational drug. This article summarizes published trial results and company releases and does not provide guidance on using unapproved products.